home / stock / glsi / glsi articles
Greenwich LifeSciences, Inc. (NASDAQ: GLSI) announced the removal of the clinical hold on the Phase III Flamingo-01 clinical trial by the U.S Food and Drug Administration (FDA).
Greenwich LifeSciences Inc. Company Name:
GLSI Stock Symbol:
NASDAQ Market:
News, Short Squeeze, Breakout and More Instantly...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the foll...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips While most people don’t like to see red ink in their investment portfolios, at the same time, that negative print comes from volatility — and volatility in either direction presents opportunities for short-ter...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the foll...